引用本文:冯迎军,李莹莹.卡维地洛与美托洛尔治疗儿童扩张型心肌病临床对比研究[J].中国临床新医学,2016,9(6):513-515.
【打印本页】   【下载PDF全文】   查看/发表评论  【EndNote】   【RefMan】   【BibTex】
←前一篇|后一篇→ 过刊浏览    高级检索
本文已被:浏览 1392次   下载 1119 本文二维码信息
码上扫一扫!
分享到: 微信 更多
卡维地洛与美托洛尔治疗儿童扩张型心肌病临床对比研究
冯迎军,李莹莹
450000 河南,郑州市儿童医院心血管内科
摘要:
[摘要] 目的 比较卡维地洛与传统的美托洛尔治疗儿童扩张型心肌病(DCM)的疗效。方法 将该院2012-09~2015-01收治的62例DCM患儿采用分层随机法分为A、B两组,每组31例。两组均常规口服地高辛、利尿剂及卡托普利。在此基础上,A组口服卡维地洛,B组口服美托洛尔,治疗6个月。超声诊断仪观察各组治疗前后左心室舒张末期内径(LVEDD)、左心室射血分数(LVEF),X线平片检查心胸比率(T/Th),电化学发光法检验N端B型脑钠肽(NT-proBNP)的变化。结果 治疗前,A组与B组的LVEDD、LVEF、T/Th、NT-proBNP指标比较差异无统计学意义(P>0.05)。治疗6个月后各项指标均明显改善(P<0.05),A组LVEDD、NT-proBNP改善程度优于B组(P<0.05),但两组LVEF、T/Th改善程度差异无统计学意义(P>0.05)。结论 卡维地洛相对于美托洛尔在治疗儿童DCM中更有优势,尤其体现在LVEDD及NT-proBNP指标的改善方面,值得临床推广。
关键词:  卡维地洛  美托洛尔  扩张型心肌病  儿童
DOI:10.3969/j.issn.1674-3806.2016.06.15
分类号:R 725
基金项目:
Effects of carvedilol and metoprolo on the children with dilated cardiomyopathy
FENG Ying-jun, LI Ying-ying
Department of Cardiovascular Medicine, Children′s Hospital of Zhengzhou, Henan 450000, China
Abstract:
[Abstract] Objective To compare the effects of Carvedilol and Metoprolo in the treatment of dilated cardiomyopath(DCM) in children.Methods Sixty-two children with DCM were collected in our hospital from September 2012 to January 2015, and were randomly divided into group A(carvedilol) and group B(metoprolo), with 31 cases in each group. Both groups were regularly treated with digoxin, diuretic and captoprilm. The improvements of left ventricular end diastolic dimension(LVEDD), left ventricular ejection fraction(LVEF), the cardiothoracic ratio measured by chest X-rayplain film(T/Th) and N-terminal pro-brain natriuretic(NT-proBNP) were compared between the two groups before and 6 months after the treatment.Results There were no significant differences between the two groups in LVEF, T/Th and NT-proBNP before the treatment(P>0.05). However, the above indicators showed significant improvements in both groups before and 6 months after the treatment(P<0.05). LVEDD and NT-proBNP were improved much significantly in group A than those in group B(P<0.05). There were no significant differences between the two groups in LVEF and T/Th(P>0.05).Conclusion Compared with metoprolol, carvedilol has more advantages in treating children with DCM, particularly in improving LVEDD and NT-proBNP indexs.
Key words:  Carvedilol  Metoprolo  Dilated cardiomyopath(DCM)  Children